IAG, Image Analysis Group

to build a strong and international community who shares knowledge and experience in upcoming digital solutions in Rheumatology. to connect leading experts from a wide variety of disciplines like Physicians, Pharma and MedTech industry, Health IT companies, Associations, Consultants and Academia as well as Research Centers to discover new innovative practices. to explore the future and understand what´s going to be next! This network aims to provide an overview on pioneering developments of therapies in digital Biomarker, artificial intelligence, applications, machine learning etc. in Rheumatology. Our community enables mutual exchange between a wide range of stakeholders and brings to the foreground innovative solutions meeting tomorrow’s challenges in Rheumatology. Data scientists, software/application developer, computer programmer, IT specialists etc.

Working with key opinion leaders on our international Medical Advisory Board, we are currently developing differentiated, first-in-class treatments that leverage alicaforsen, an antisense therapeutic agent with a novel target for validated mechanism of action and the potential to treat multiple inflammatory GI diseases. Our mission is to work collaboratively with healthcare providers and patient groups in pursuit of treatments which improve the quality of life of patients with unmet medical needs. Our vision is to be acknowledged as a leading global specialist pharmaceutical company with a portfolio of therapeutics that meet the needs of patients, healthcare providers and the wider healthcare community, while providing acceptable shareholder returns. Our Board offers a wealth of experience in growing successful pharmaceutical companies, having held leadership roles in large multi-national firms. Our international Medical Advisory Board comprises a group of eminent clinicians who provide expert advice and counsel to inform the development of our pipeline.

Led by a world class management and advisory team with complementary expertise in the pathobiology of autoimmune diseases, computational biology, medicinal chemistry, drug development, clinical trial design, and regulatory strategy. We believe the solution to complex diseases requires a system based approach.

Together, we are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. We are industry experts and scientific pioneers working together to bring an entirely new approach to the treatment of autoimmune disease. Daniel is a founder of the North American Imaging in MS (NAIMS) Cooperative. Roland is a member of the Kuratorium of the Jung Foundation for Science in Hamburg, member of the core faculty of the Wyss Center Zürich, co-founder of the Drug Discovery Network Zurich and co-founder of the Therapy Development Accelerator at the University of Zürich. Abbie Celniker has more than 30 years of experience in senior R&D and executive leadership roles. Abbie is a member of the scientific advisory board for Adimab and is a current board member and the former chair of MassBio. As executive partner of MPM Capital, Mitch has been instrumental in founding, building and leading a number of MPM portfolio companies. Samantha is a member of the board of directors of the Institute for Protein Innovation.

We are proud to partner with recognized global leaders in academia, research, and industry to deliver transformative treatment options and improve access for those living with autoimmune diseases. Today, we are actively partnering with Otsuka to commercialize LUPKYNIS® in the EU and the UK. We are honored to have been recognized for our leadership by both healthcare industry experts and community leaders. We are a proven, passionate team committed to changing the trajectory of autoimmune diseases. See how we are poised to deliver on our mission. Working tirelessly, they assembled a team of passionate individuals with expertise in drug research, development and commercialization, and sought like-minded partners to enable the delivery of transformative treatments to as many patients as possible, as soon as possible. Committed to changing the trajectory of autoimmune diseases, our leaders bring decades of experience in scientific innovation, drug development and commercialization, and corporate strategy. Collaboration powers success and we are committed to forging strategic partnerships that advance our mission.

PredictImmune, our academic founders, our partners and our investors have worked hard over the last six years to bring PredictSURE IBD to market with the aim of improving patient outcomes. Amanda is currently a Director of PredictImmune Limited and served on the board of Sphere Fluidics Limited for six years. Lea Ann Chen, MD, AGAF, FACG is the Director of Inflammatory Bowel Disease Translational Research at Rutgers Robert Wood Johnson School of Medicine in New Brunswick, NJ. Karen recognises the importance of working closely with sales and marketing teams to provide them with the tools they need to raise awareness of products in their regions and generate ongoing business. Dr Michael Anstey is a Partner at Cambridge Innovation Capital (CIC) specialising in life sciences investments. Dr James Lee is a Consultant Gastroenterologist at the Royal Free Hospital London and a Clinician Scientist Group Leader at the Francis Crick Institute. VP Delivery and a Principal Research Associate in the Department of Medicine with a research interest focused on understanding the underlying basis of immune-mediated disease. Paul is a seasoned CFO, having been Finance Director at NovaBiotics Ltd, Venn Life Sciences plc, Elsevier Science, Porta Communications plc, Hansard Group plc and Curidium Medica plc, amongst others.